Migraines are less common in people with diabetes

September 18, 2021

Two large studies have established that if you have diabetes you are less likely to suffer from migraines.

The first study was done on the entire population of Norway. The authors concluded that both type 1 and type 2 diabetes are significantly associated with a decreased risk of migraine.

The second study involved 74,247 French women. The researchers discovered that there was a lower risk of developing type 2 diabetes in women with active migraine. They also found that migraine was less common even prior to the development of diabetes.

Being overweight increases the frequency of migraines. Losing weight by any method, including bariatric surgery, improves migraines. There have been no studies of diabetes drugs in the treatment of migraines.

However, I do prescribe a diabetes drug metformin to migraine patients who are overweight or develop migraines when they are hungry. Metformin helps lose weight by maintaining a steady level of blood sugar. It does this by regulating the release of glucose from the liver. It also has anti-inflammatory properties.

Another diabetes drug, semaglutide in injections (Wegovy and Ozempic) and tablets (Rybelsus) is even more effective for weight reduction than metformin. Semaglutide, unlike metformin, is approved by the FDA for weight loss even in the absence of diabetes.

It is possible that the treatment of diabetes reduces the risk of developing migraines. The French study, however, suggests that other factors could play a role as well.

Written by
Alexander Mauskop, MD
Continue reading
August 8, 2026
Sugar is bad for your brain, even before you are born.
Sugar consumed in the first two years of life increases the risk of dementia.
Read article
August 6, 2026
Research
An Old Medicine that Could Make Brain Stimulation Work Better for Depression and Other Neurological Conditions
A 2022 clinical trial from the University of Calgary found that adding low‑dose D‑cycloserine (DCS), a partial NMDA‑receptor agonist, to intermittent theta‑burst stimulation (iTBS) significantly increased response and remission rates in depression without serious side effects. Early follow‑up data suggest that timing, dose, and drug levels matter, and raise the possibility that this DCS‑TMS approach could eventually be applied to other neurological conditions—such as migraine, postconcussion syndrome, brain fog, and long COVID
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe